Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado's two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia.
November 7, 2013:
Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation To Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease
November 6, 2013:
November 1, 2013:
October 14, 2013:
CNDO Coronado Biosciences Announces Top-line Results from TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn’s DiseaseCORONADO IN THE NEWS
April 23, 2013:
The Hygiene Hypothesis: Too Clean for Our Own Good?
By: Chris Leach at Insulin Nation
April 8, 2013:
TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis.
CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.
ONGOING CLINICAL TRIALS
Click here for more clinical trial information.